19.75
Schlusskurs vom Vortag:
$19.44
Offen:
$19.44
24-Stunden-Volumen:
3.23M
Relative Volume:
1.35
Marktkapitalisierung:
$14.57B
Einnahmen:
$956.00K
Nettoeinkommen (Verlust:
$-196.68M
KGV:
-82.29
EPS:
-0.24
Netto-Cashflow:
$-113.02M
1W Leistung:
-5.00%
1M Leistung:
-10.71%
6M Leistung:
-19.02%
1J Leistung:
+456.34%
Summit Therapeutics Inc Stock (SMMT) Company Profile
Firmenname
Summit Therapeutics Inc
Sektor
Branche
Telefon
305-203-2034
Adresse
601 BRICKELL KEY DRIVE, MIAMI
Vergleichen Sie SMMT mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
SMMT
Summit Therapeutics Inc
|
19.75 | 14.57B | 956.00K | -196.68M | -113.02M | -0.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
503.20 | 129.22B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
658.48 | 71.99B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
615.02 | 37.37B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
283.34 | 36.68B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
251.98 | 27.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-03-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
2025-03-12 | Eingeleitet | Evercore ISI | Outperform |
2025-02-28 | Eingeleitet | Goldman | Buy |
2025-01-08 | Eingeleitet | Truist | Buy |
2024-12-11 | Eingeleitet | Wells Fargo | Overweight |
2024-12-06 | Eingeleitet | Jefferies | Buy |
2024-11-04 | Eingeleitet | JMP Securities | Mkt Outperform |
2024-09-27 | Herabstufung | Citigroup | Buy → Neutral |
2024-08-12 | Eingeleitet | H.C. Wainwright | Buy |
2024-05-07 | Eingeleitet | Citigroup | Buy |
2024-03-26 | Eingeleitet | Stifel | Buy |
2018-06-28 | Herabstufung | Janney | Buy → Neutral |
2018-05-02 | Eingeleitet | Janney | Buy |
2018-04-12 | Bestätigt | Needham | Buy |
2018-02-13 | Eingeleitet | BTIG Research | Buy |
2018-01-04 | Eingeleitet | SunTrust | Buy |
2017-12-01 | Fortgesetzt | H.C. Wainwright | Buy |
2016-11-16 | Bestätigt | RBC Capital Mkts | Outperform |
2016-10-05 | Bestätigt | Needham | Buy |
2016-09-16 | Eingeleitet | H.C. Wainwright | Buy |
2015-03-30 | Eingeleitet | Needham | Buy |
2015-03-30 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Summit Therapeutics Inc Aktie (SMMT) Neueste Nachrichten
Is Summit Therapeutics a Millionaire Maker? - Nasdaq
Cantor Fitzgerald Initiates Coverage of Summit Therapeutics (BMV:SMMT) with Overweight Recommendation - Nasdaq
Summit rises as Cantor becomes latest to launch with a bullish view - MSN
Cantor Fitzgerald Initiates Coverage of Summit Therapeutics (SMMT) with Overweight Recommendation - Nasdaq
Summit Therapeutics grants stock options to new employees By Investing.com - Investing.com Canada
Summit Therapeutics grants stock options to new employees - Investing.com India
Summit Therapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4) -March 21, 2025 at 04:20 pm EDT - Marketscreener.com
Summit Therapeutics Awards 147,500 Shares in Strategic Employee Stock Options - StockTitan
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance UK
Summit stock rises after Cantor's bullish view (SMMT:NASDAQ) - Seeking Alpha
Cantor Fitzgerald Initiates Summit Therapeutics at Overweight -March 21, 2025 at 07:27 am EDT - Marketscreener.com
This Unstoppable Biotech Stock Just Became an Even Better Buy - The Globe and Mail
Summit Therapeutics Names Robert LaCaze as Chief Commercial Officer -March 18, 2025 at 03:30 am EDT - Marketscreener.com
Summit Therapeutics : Completion of $50 million Fundraising and Directorate Change - Marketscreener.com
Billion-Dollar Oncology Expert Robert LaCaze to Drive Summit Therapeutics Cancer Drug Launch - StockTitan
Evercore ISI Group Initiates Coverage of Summit Therapeutics (BMV:SMMT) with Outperform Recommendation - Nasdaq
Summit gains as Evercore highlights potential to rival Merck’s Keytruda - MSN
Applovin, Super Micro Computer And Intel Among Top 10 Large-Cap Gainers Last Week (Mar 10-Mar 14): Are The Others In Your Portfolio? - Benzinga
Summit Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:SMMT - Benzinga
(SMMT) On The My Stocks Page - Stock Traders Daily
Summit Therapeutics issues stock options to new employees By Investing.com - Investing.com Australia
Summit Therapeutics issues stock options to new employees - Investing.com India
Summit Therapeutics Awards 122,650 Shares in Employee Stock Options at $18.50 - StockTitan
Summit Therapeutics Stock Climbs 4%, Share Price Hits $19.96 - TradingPedia
Why Summit Therapeutics Stock Was Winning This Week - MSN
SMMT Gains on Bullish Analyst Coverage - GuruFocus.com
Summit Therapeutics (NASDAQ:SMMT) Coverage Initiated at Evercore ISI - Defense World
Is Summit Therapeutics Inc. (SMMT) the Best Multibagger Stock to Buy in 2025? - Insider Monkey
This Could Be the Catalyst That Sends Summit Therapeutics' Stock Higher This Year - Nasdaq
Evercore ISI Initiates Summit Therapeutics at Outperform With $30 Price Target -March 12, 2025 at 12:08 pm EDT - Marketscreener.com
Summit Therapeutics Shares Surge on Promising Trial Results - TipRanks
Evercore ISI Group Initiates Coverage of Summit Therapeutics (SMMT) with Outperform Recommendation - Nasdaq
Summit Therapeutics initiated with an Outperform at Evercore ISI - TipRanks
12 Best Multibagger Stocks to Buy in 2025 - Insider Monkey
Stifel maintains Buy on Summit Therapeutics, $40 target By Investing.com - Investing.com Canada
Summit Therapeutics Inc. (SMMT): Why Are Analysts Bullish On This Hot Growth Stock Right Now? - Insider Monkey
New York State Common Retirement Fund Grows Stake in Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World
Principal Financial Group Inc. Acquires 147,003 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World
Summit Therapeutics (NASDAQ:SMMT) Stock Rating Upgraded by StockNews.com - Defense World
(SMMT) Investment Analysis and Advice - Stock Traders Daily
Rhumbline Advisers Has $2.23 Million Stock Position in Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World
Summit Therapeutics (NASDAQ:SMMT) Earns Buy Rating from Analysts at The Goldman Sachs Group - MarketBeat
Equities Analysts Offer Predictions for SMMT Q1 Earnings - MarketBeat
Summit Therapeutics' (SMMT) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Goldman Sachs Initiates Coverage of Summit Therapeutics (SMMT) with Buy Recommendation - MSN
StockNews.com Downgrades Summit Therapeutics (NASDAQ:SMMT) to Sell - MarketBeat
This CoStar Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Summit Therapeutics Stock Surges Amid Promising Trials - TipRanks
Goldman Sachs Initiates Summit Therapeutics at Buy With $42 Price Target -February 28, 2025 at 08:12 am EST - Marketscreener.com
Finanzdaten der Summit Therapeutics Inc-Aktie (SMMT)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):